Keratoacanthoma - Keratoakantoma
☆ 2022 m. Stiftung Warentest iš Vokietijos rezultatai rodo, kad vartotojų pasitenkinimas ModelDerm buvo tik šiek tiek mažesnis nei mokamų nuotolinės medicinos konsultacijų.
Tipiškas Keratoakantoma (Keratoacanthoma)
References
Keratoacanthoma (KA) yra dažnas odos auglys, žinomas dėl greito augimo ir galimo savaime regresuoti. Paprastai tai pasireiškia vyresnio amžiaus, šviesios odos vyrams, kuriems anksčiau buvo saulės žalos. Nors chirurginis pašalinimas naudojant eksciziją arba Mohso mikrografinę chirurgiją yra įprastas gydymas, yra įvairių kitų gydymo galimybių.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) yra žemo laipsnio navikas, kuris prasideda tam tikrose odos liaukose ir mikroskopu atrodo panašiai kaip squamous cell carcinoma (SCC) . Vyksta diskusijos apie tai, ar KA turėtų būti klasifikuojama kaip invazinio SCC forma.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) yra antras dažniausiai pasitaikantis vėžio tipas tarp žmonių, ypač tarp vyresnio amžiaus žmonių. Chirurgija paprastai naudojama cSCC gydyti, tačiau kai kuriems pacientams, kurie negali atlikti operacijos arba nenori to daryti, gali būti svarstomos kitos galimybės, pvz. , Intralesioninis gydymas. Buvo naudojami tradiciniai intralesioniniai gydymo būdai (methotrexate or 5-fluorouracil) , tačiau vyksta naujų metodų, tokių kaip intralesioninė imunoterapija ir onkolitinė viroterapija, tyrimai. Čia apžvelgsime skirtingus cSCC intralesioninius gydymo būdus, pradedant klasikiniais metodais ir baigiant pažangiausiomis strategijomis.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Žiūrint mikroskopu, keratoakantoma (keratoacanthoma) labai panaši į plokščialąstelinę karcinomą. Nors kai kurie patologai keratoakantoma (keratoacanthoma) klasifikuoja kaip atskirą darinį, o ne piktybinį naviką, apie 6 % klinikinių ir histologinių keratoakantoma (keratoacanthoma) progresuoja į invazinį ir agresyvų plokščiųjų ląstelių vėžį.
○ Diagnostika ir gydymas
#Dermoscopy
#Skin biopsy